Intractable Pain Clinical Trial
Official title:
Acceptance-Based Treatment for Chronic Pain
| Verified date | March 2015 |
| Source | VA Office of Research and Development |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Federal Government |
| Study type | Interventional |
The purpose of the study is to test a brief, group-administered psychosocial intervention to reduce interference of pain with daily life, emotional distress, and pain intensity, and improve quality of life and physical activity levels in individuals with chronic pain.
| Status | Completed |
| Enrollment | 114 |
| Est. completion date | September 2009 |
| Est. primary completion date | December 2008 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Age 18 years old or older; - Proficient in English; - Willing and able to provide written informed consent (proposed informed consent form attached as Appendix A); - Diagnosis of chronic benign pain as a secondary condition associated with a primary impairment due to a traumatic injury or congenital or acquired disorder as verified by a study physician after a medical diagnostic evaluation; - Average pain severity rated > 4/10 with resulting functional limitations; and - Pain duration of at least 6 months. Exclusion Criteria: - Participation in psychotherapy for pain the past 2 months; - Serious, unstable medical illness for which inpatient hospitalization is likely over the next 3 months; and - The following DSM-IV diagnoses or active problems within the past 6 months noted in the patient's CPRS medical record or diagnosed during a structured psychiatric interview: 1) schizophrenia; 2) other psychotic disorder; 3) bipolar disorder; 4) organic mental disorder; 5) borderline or antisocial personality disorder; or 6) alcohol or substance abuse or dependence. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | VA San Diego Healthcare System, San Diego | San Diego | California |
| Lead Sponsor | Collaborator |
|---|---|
| VA Office of Research and Development |
United States,
Mostoufi SM, Afari N, Ahumada SM, Reis V, Wetherell JL. Health and distress predictors of heart rate variability in fibromyalgia and other forms of chronic pain. J Psychosom Res. 2012 Jan;72(1):39-44. doi: 10.1016/j.jpsychores.2011.05.007. Epub 2011 Jun 3 — View Citation
Wetherell JL, Afari N, Rutledge T, Sorrell JT, Stoddard JA, Petkus AJ, Solomon BC, Lehman DH, Liu L, Lang AJ, Atkinson JH. A randomized, controlled trial of acceptance and commitment therapy and cognitive-behavioral therapy for chronic pain. Pain. 2011 Se — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Brief Pain Inventory | This questionnaire measures pain severity and interference. Scores range from 0-10, with higher scores indicating more pain. | 12 weeks (post treatment) | No |
| Secondary | West Haven-Yale Multidimensional Pain Inventory - Activity Subscales | This questionnaire measures levels of activity that can be affected by pain. Full measure has a range of 0-6, with higher scores indicating higher levels of activity. | 12 weeks (post treatment) | No |
| Secondary | SF-12 | This questionnaire measures quality of life. Scores range from 0 to 100, with higher scores indicating better quality of life. | 12 weeks (post treatment) | No |
| Secondary | Beck Depression Inventory | This questionnaire measures depressive symptoms. Scores range from 0 to 63, with higher scores indicating higher levels of depressive symptoms. | 12 weeks (post treatment) | No |
| Secondary | Pain Anxiety Symptom Scale - 20 | This questionnaire measures pain-related anxiety. Scores range from 0 to 100, with higher scores indicating higher levels of anxiety. | 12 weeks (post treatment) | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00996983 -
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
|
Phase 2 | |
| Withdrawn |
NCT03876158 -
Transitioning to a Valve -Gated Intrathecal Drug Delivery System (IDDS)
|
Phase 4 | |
| Not yet recruiting |
NCT02522611 -
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04909593 -
Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial
|
N/A | |
| Terminated |
NCT02587130 -
Ketamine and Refractory Painful Care in a Palliative Unit
|
Phase 4 | |
| Terminated |
NCT03886753 -
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products
|
||
| Completed |
NCT03082261 -
Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator
|
N/A | |
| Completed |
NCT01854229 -
Prometra Post-Approval Study
|
N/A | |
| Completed |
NCT01291901 -
NP2 Enkephalin For Treatment of Intractable Cancer Pain
|
Phase 2 | |
| Completed |
NCT00817596 -
Prometra's Utilization in Mitigating Pain (PUMP)
|
N/A | |
| Completed |
NCT01567345 -
Intrathecal Morphine Administration Using Implantable Pump With Continuous or Programmable Flow
|
N/A | |
| Terminated |
NCT00387244 -
Efficacy of the Spinal Cord Stimulation System as Salvage Therapy
|
N/A | |
| Recruiting |
NCT00804154 -
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
|
Phase 1 | |
| Approved for marketing |
NCT00866164 -
Prometra's Utilization in Mitigating Pain II
|
N/A |